CARA - Cara Therapeutics EPS beats by $0.12 misses on revenue
Cara Therapeutics (CARA): Q1 GAAP EPS of -$0.47 beats by $0.12.Revenue of $1.94M (-76.0% Y/Y) misses by $0.65M.Cash, cash equivalents and marketable securities at March 31, 2021 totaled $228.3 million compared to $251.5 million at December 31, 2020. Guidance: Cara expects that its existing unrestricted cash and cash equivalents and available-for-sale marketable securities as of March 31, 2021 will be sufficient to fund its currently anticipated operating expenses and capital expenditures into 2023, without giving effect to any potential milestone payments or potential product revenue under existing collaborations.Press Release
For further details see:
Cara Therapeutics EPS beats by $0.12, misses on revenue